- Home
- COLL vs DCOM Comparison
COLL vs DCOM Comparison
Compare COLL & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | DCOM |
|---|---|---|
| Founded | 2002 | 1864 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | DCOM |
|---|---|---|
| Price | $37.27 | $31.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $50.83 | $36.40 |
| AVG Volume (30 Days) | ★ 387.1K | 204.1K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $6.07 | $21.40 |
| Revenue Next Year | N/A | $12.65 |
| P/E Ratio | $21.55 | ★ $14.81 |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $23.23 | $23.25 |
| 52 Week High | $50.79 | $36.86 |
Technical Indicators
Market Signals| Indicator | COLL | DCOM |
|---|---|---|
| Relative Strength Index (RSI) | 21.42 | 38.96 |
| Support Level | $34.30 | $25.67 |
| Resistance Level | $39.85 | $34.86 |
| Average True Range (ATR) | 1.61 | 1.25 |
| MACD | -0.83 | -0.34 |
| Stochastic Oscillator | 9.89 | 20.52 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.